Skip to main content

Advertisement

SpringerLink
Log in

Recent Developments in the Classification, Evaluation, Pathophysiology, and Management of Scleroderma Renal Crisis

  • Scleroderma (J Varga, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Scleroderma renal crisis (SRC) is an uncommon complication of systemic sclerosis. Despite the advent of angiotensin-converting inhibitor therapy, SRC remains a life-threatening complication. Recent studies have contributed to a better understanding of SRC, but much remains unknown regarding its pathophysiology, risk factors, and optimal management. Genetic studies provide evidence that immune dysregulation might be a contributing factor, providing hope that further research in this direction might illuminate pathogenesis and provide novel predictors for this complication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Steen V, Costantino J, Shapiro A, Medsger T. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme inhibitors. Ann Intern Med. 1990;113:352–7.

    Article  CAS  PubMed  Google Scholar 

  2. Cozzi F, Marson P, Cardarelli S, Favaro M, Tison T, Tonello M, et al. Prognosis of scleroderma renal crisis: a long term observational study. Nephrol Dial Transplant. 2012;27:4398–403.

    Article  CAS  PubMed  Google Scholar 

  3. Guillevin L, Berezne A, Seror R, Teixeira L, Pourrat J, Mahr A, et al. Scleroderma renal crisis: a retrospective multicenter study on 91 patients and 427 controls. Rheumatology. 2012;51:460–7. This is a retrospective evaluation of 91 SRC patients compared to non-SRC SSc control patients. It describes characteristics, prognosis, and outcome of SRC patients.

    Article  CAS  PubMed  Google Scholar 

  4. Penn H, Howie A, Kingdon EJ, Bunn C, Stratton R, Black C, et al. Scleroderma renal crisis: patient characteristics and long term outcomes. Q J Med. 2007;100:485–94.

    Article  CAS  Google Scholar 

  5. Texeira L, Mouhon L, Mahr A, Berezne A, Agard C, Mehrenberger M, et al. Mortality and risk factors of scleroderma renal crisis a French retrospective study of 50 patients. Ann Rheum Dis. 2008;67:110–6.

    Article  Google Scholar 

  6. Logee KM, Laksminarayanan S. Scleroderma renal crisis as an initial presentation of systemic sclerosis: a case report and review of the literature. Clin Exp Rheumatol. 2015.

  7. Steen VD, Mayes MD, Merkel PA. Assessment of kidney involvement. Clin Exp Rheumatol. 2003;21 suppl 29:S29–31.

  8. Hudson M, Baron M, Tatibouet S, Furst D, Khanna D. Exposure to ACE inhibitors prior to onset of scleroderma renal crisis—results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum. 2014;43:666–72. This is a prospective cohort study showing that prior exposure to ACE inhibitors was associated with an increased risk of death after onset of scleroderma renal crisis.

    Article  CAS  PubMed  Google Scholar 

  9. KDIGO Clinical Practice Guideline for acute kidney injury. Kidney International 2012: 2 supplement

  10. Marighela TF, Genaro PS, Pinheiro MM, Szejnfeld VL, Kayser C. Risk factors for body composition abnormalities in systemic sclerosis. Clin Rheumatol. 2013;32:1037–44.

    Article  PubMed  Google Scholar 

  11. Amin A, El-Sayed S, Taher N, Sedki M, Nasr H. Tc-99m diethylenetriamine pentaacetic acid (DTPA) renal function reserve estimation: is it a reliable predictive tool for assessment of preclinical renal involvement in scleroderma patients? Clin Rheumatol. 2012;31:961–6.

    Article  PubMed  Google Scholar 

  12. Guerra S et al. Defining genetic risk for scleroderma renal crisis. Rheumatology. 2014;54:654–66.

    Google Scholar 

  13. Fonseca C, Renzoni E, et al. Endothelin axis polymorphisms in patients with scleroderma. Arthritis Rheum. 2006;54:3034–42.

    Article  CAS  PubMed  Google Scholar 

  14. Mouthon L et al. Endothelin-1 expression in scleroderma renal crisis. Hum Pathol. 2011;42:95–102.

    Article  CAS  PubMed  Google Scholar 

  15. Kobayashi H, Nishimaki T, Kaise S, Suzuki T, et al. Immunohistological study of endothelin-1 and endothelin-A and B receptors in two patients with scleroderma renal crisis. Clin Rheumatol. 1999;18:425–7.

    Article  CAS  PubMed  Google Scholar 

  16. Becker MO, Kill A, et al. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Resp Crit Care Med. 2014;190:808–17.

    Article  CAS  PubMed  Google Scholar 

  17. Guillevin L, Mouthon L. Scleroderma renal crisis. Rheum Dis Clin N Am. 2015. 475–488.

  18. Batal I, Domsic R, Shafer A, Medsger T, Kiss L, Randhawa P, et al. Renal biopsy findings prediction outcome in scleroderma renal crisis. Hum Pathol. 2009;40:332–40.

    Article  PubMed  Google Scholar 

  19. Yamada Y, Suzuki K, Nobata H, Kawai H, Wakamatsu R, Miura N, et al. Gemcitabine-induced hemolytic uremic syndrome mimicking scleroderma renal crisis presenting with Raynaud’s phenomenon, positive antinuclear antibodies and hypertensive emergency. Intern Med. 2014;53(5):445–8.

    Article  PubMed  Google Scholar 

  20. Abudiab M, Krause ML, Fidler ME, Nath KA, Norby SM. Differentiating scleroderma renal crisis from other causes of thrombotic microangiopathy in a postpartum patient. Clin Nephrol. 2013;80(4):293–7.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Keeler E, Fioravanti G, Samuel B, Longo S. Scleroderma renal crisis or thrombotic thrombocytopenic purpura: seeing through the masquerade. Lab Med. 2015;46(2):e39–44.

    Article  PubMed  Google Scholar 

  22. Bhasavar S, Carmona R. Anti-RNA polymerase III antibodies in the diagnosis of scleroderma renal crisis in the absence of skin disease. JCR: J Clin Rheumatol. 2014;20:379–82.

    Google Scholar 

  23. Fred H, Rambo O. Acute renal failure due to scleroderma kidney disease; a report of one case with autopsy findings. AMA Arch Intern Med. 1957;100(5):813–8.

    Article  CAS  PubMed  Google Scholar 

  24. Batal I, Domsic R, Medsger T Bastacky S. Scleroderma renal crisis: a pathology perspective. Int J Rheumatol. 2010. 1–5

  25. Steen V, Medsger T. Changes in causes of death in systemic sclerosis 1972–2002. Ann Rheum Dis. 2007;66:940–4.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Wasner C, Cooke CR, Fries JF. Successful medical treatment of scleroderma renal crisis. N Engl J Med. 1978;299(16):873–5. This report describes the treatment of SRC with oral anti hypertensive medications other than Ace inhibitors.

    Article  CAS  PubMed  Google Scholar 

  27. Lopez-Ovejero J, Saal SD, D’Angelo WA, Cheigh JS, et al. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N Engl J Med. 1979;300:1417–9. This report describes the first successful treatment of SRC with ACE inhibitors.

    Article  CAS  PubMed  Google Scholar 

  28. Caskey FJ, Thacker EJ, Johnston PA, Barnes JN. Failure of losartan to control blood pressure in scleroderma renal crisis. Lancet. 1997;349(9052):620.

    Article  CAS  PubMed  Google Scholar 

  29. Cheung WY, Gibson IW, Rush D, Jeffery J, Karpinski M. Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade. Am J Kidney Dis. 2005;45:930–4.

    Article  PubMed  Google Scholar 

  30. Dhaun N, MacIntyre IM, Bellamy CO, Kluth DC. Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney. Am J Kidney Dis. 2009;54(4):726–31.

    Article  CAS  PubMed  Google Scholar 

  31. Penn H, Quillian N, et al. Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. Quart L Med. 2013;106(9):839–48. This study is a pilot open-label study looking at ET1 expression in patients with SRC and determined the safety and possible benefit of the use of ET1 antagonist in this disease.

    Article  CAS  Google Scholar 

  32. Bose N, Chiesa-Vottero A, Chatterjee S. Scleroderma renal crisis. Semin Arthritis Rheum. 2015;44:687–94.

    Article  CAS  PubMed  Google Scholar 

  33. Steen VD, Medsger Jr TA. Long-term outcomes of scleroderma renal crisis. Ann Intern Med. 2000;133(8):600–3.

    Article  CAS  PubMed  Google Scholar 

  34. Denton C, Black C. Scleroderma—clinical and pathological advances. Best Pract Res Clin Rheumatol. 2004;18:271–90.

    Article  CAS  PubMed  Google Scholar 

  35. Penn H, Denton CP. Diagnosis, management and prevention of scleroderma renal disease. Curr Opin Rheumatol. 2008;20(6):692–6.

    Article  PubMed  Google Scholar 

  36. Fenves AZ, Murphy JS, Emmett M. Scleroderma renal crisis and recovery from end-stage renal disease. Semin Dial. 1998;11(3):189–91.

    Article  Google Scholar 

  37. Pham PT, Pham PC, Danovitch GM, Gritsch A, et al. Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature. Am J Transplant. 2005;5(10):2565–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Nephrology, Northwestern University, Feinberg School of Medicine, 710 North Fairbanks Court—Suite 4500, Chicago, IL, 60611, USA

    Cybele Ghossein

  2. Department of Medicine, Northwestern University, Feinberg School of Medicine, 240 E Huron Street McGaw Pavilion Rheumatology M300, Chicago, IL, 60611, USA

    John Varga

  3. Department of Medicine, Division of Rheumatology, Northwestern University, Feinberg School of Medicine, 240 E Huron Street McGaw Pavilion Rheumatology M300, Chicago, IL, 60611, USA

    John Varga

  4. Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 50 Staniford Street, Suite 503B, Boston, MA, 02114, USA

    Andrew Z. Fenves

Authors
  1. Cybele Ghossein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Varga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew Z. Fenves
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cybele Ghossein.

Ethics declarations

Conflict of Interest

The authors declare that they have no competing interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Scleroderma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ghossein, C., Varga, J. & Fenves, A.Z. Recent Developments in the Classification, Evaluation, Pathophysiology, and Management of Scleroderma Renal Crisis. Curr Rheumatol Rep 18, 5 (2016). https://doi.org/10.1007/s11926-015-0551-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-015-0551-y

Keywords

Search

Navigation